RMAT Designation Supports an Expedited FDA Development and Review Pathway for Aspen's Investigational Autologous Cell Replacement Therapy for Parkinson's Disease.

SOLANA BEACH, CA / ACCESS Newswire / July 31, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulated its partner Aspen Neuroscience, Inc. on receiving Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for sasineprocel (ANPD001), Aspen's investigational autologous dopaminergic neuron cell replacement therapy for Parkinson's disease.

Highlights

The FDA has granted RMAT designation for sasineprocel, Aspen Neuroscience's investigational autologous cell replacement therapy for Parkinson's disease.

RMAT designation provides benefits such as early and frequent interactions with the FDA, and potential eligibility for priority review and/or accelerated approval.

The ClearPoint Neuro Navigation System and the SmartFlow® Cannula have been used for the transplantation procedure in Aspen's ASPIRO clinical trial, as announced in June 2024.

ClearPoint currently supports 60+ biologics and drug delivery partner programs, of which 10+ have received one or more expedited review designations to-date.

 

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.